Diagnostics channel feed – Endpoints News

Diagnostics channel feed

Illumina to divest Grail, two years after $8B deal was stymied by antitrust issues

Last year

Illumina expects revenue drop after another guidance cut

Last year

Carl Icahn sues Illumina board members over Grail acquisition

Last year

VedaBio launches with $40M+ in initial funding for CRISPR-based molecular detection technology

Last year

Illumina receives EU order to divest Grail

Last year

Exclusive: Liquid-biopsy startup closes $17M to fund ovarian cancer diagnostic test

Last year

BMS-backed liquid biopsy biotech Precede Biosciences debuts to enhance precision medicine approaches

Last year

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

Last year

Element Biosciences logs 100 DNA sequencer orders as it gains momentum in a competitive market

Last year

Illumina began hunt for CEO candidates in midst of activist fight, eventually picking little-known diagnostics exec

Last year

Illumina names former Agilent exec as CEO, months after parting ways with deSouza

Last year

PacBio, once slated to be acquired by Illumina, is taking on the DNA giant

Last year

His tiny prenatal testing company has big plans after exacting legal revenge on lab giants

Last year

Diagnostics outfit lays off third of employees, now looking at 'strategic alternatives'

Last year

FDA warns some Illumina DNA sequencing devices could be vulnerable to hackers

3 years ago

Quest Diagnostics buys Bert Vogelstein’s Haystack Oncology, just six months after Series A

3 years ago

Pattern Bioscience raises $28.7M Series C for faster, more efficient antibiotic resistance test

3 years ago

As showdown with activist nears, Illumina’s CEO defends the company’s $7.1B purchase of Grail

3 years ago

Ex-US Commerce Secretary Wilbur Ross pairs his SPAC with Alzheimer's biotech

3 years ago

Qiagen picks up DNA forensics company for $150M

3 years ago

Thermo Fisher wagers on early cancer diagnostics in $2.6B cash deal for multiple myeloma test maker

3 years ago

After blocking Grail acquisition, EU leaves Illumina with few good options

3 years ago

China's DNA giant confronts skepticism in US expansion bid

3 years ago

Korean diagnostics biotech goes transpacific, agreeing to shell out $1.5B to take Meridian private

3 years ago

First page Previous page 1 234 Next page Last page